7/29/2013 | HY | Moody's might lift Elan
|
7/29/2013 | BKIG | S&P: Perrigo view negative
|
6/20/2013 | HYLM | Elan Finance redeems all $850 million of its 61/4% senior notes due 2021
|
6/14/2013 | HY | Moody's: Elan view to developing
|
6/5/2013 | HYLM | Elan CEO sheds light on use of cash, comments on takeover bid
|
5/24/2013 | HY | Market Commentary: Junk primary falls silent ahead of holiday; new Elan, Century hold their own; Exide, Sears slide
|
5/24/2013 | HY | Market Commentary: Midday Commentary: Elan, Provident bonds outperforming amid overall weakness before holiday
|
5/23/2013 | HY | New Issue: Elan prices upsized $850 million eight-year notes at par to yield 61/4%
|
5/23/2013 | HY | Market Commentary: Elan leads $1.82 billion primary ahead of sleepy Friday; Europe busy; funds gain $376 million
|
5/22/2013 | HY | Elan talks $800 million eight-year notes to yield in 61/4% area
|
5/22/2013 | HY | Market Commentary: CommScope, Provident, Legacy, Vantage price in $1.8 billion day; US Air makes return flight
|
5/20/2013 | HY | Ireland's Elan on roadshow for $800 million notes via Morgan Stanley
|
5/20/2013 | HY | Moody's rates Elan Finance notes Ba3
|
5/20/2013 | HY | Market Commentary: B&G Foods, Sabra bring deals; Concho, Memorial Production do add-ons; calendar keeps building
|
5/20/2013 | HYLM | Ireland's Elan creates 'balance of risk' with $800 million debt offering, acquisitions, divestiture
|
5/13/2013 | HY | Moody's could cut Elan
|
4/24/2013 | HY | Market Commentary: Midday Commentary: Schaeffler, Realogy new deals hold near initial trading levels
|
4/2/2013 | HYLM | Elan to redeem all $600 million of its 61/4% senior notes on May 2
|
3/15/2013 | HY | S&P affirms Elan
|
2/6/2013 | HY | Elan restructures Tysabri venture, gets $3.25 billion cash; no plans for debt repayment with proceeds
|
12/20/2012 | HY | Moody's lifts Elan
|
10/23/2012 | HYLM | Elan gets no more tenders after consent deadline for 83/4% notes
|
10/9/2012 | HYLM | Elan units get tenders, consents to amend two series of 83/4% notes
|
10/1/2012 | HYLM | Elan to redeem all $624.5 million of senior notes due 2016 on Oct 31
|
9/27/2012 | HY | Market Commentary: Ryerson, Regency deals lead nearly $4 billion day; market improves, but funds lose $310 million
|
9/25/2012 | HY | Market Commentary: Junk market ends with softer tone; ArcelorMittal brings new hybrid; commodity credits get cheap
|
9/25/2012 | HY | Elan intends to price $500 million seven-year senior notes
|
9/25/2012 | HY | New Issue: Elan prices upsized $600 million seven-year notes at par to yield 61/4%
|
9/25/2012 | HY | S&P rates Elan notes BB-
|
9/25/2012 | HY | Moody's rates Elan notes B1
|
9/24/2012 | HYLM | Elan subsidiaries tender, seek consents for two series of 83/4% notes
|
9/24/2012 | HY | Elan intends to sell new senior notes to fund tender offers
|
9/24/2012 | HY | Market Commentary: Gray TV, Frontier, Ply Gem, BreitBurn price; calendar builds; Calpine terminates deal
|
8/13/2012 | HY | Moody's could lift Elan
|
8/13/2012 | HY | S&P: Elan on watch
|
8/13/2012 | HYLM | Elan to ask holders of 83/4% notes due 2016 to approve Neotope spinoff
|
3/6/2012 | SP | New Issue: RBC prices $2.27 million 10.13% airbag yield optimization notes on Elan
|
3/1/2012 | SP | RBC plans 7.7%-10.2% airbag yield optimization notes linked to Elan
|
2/29/2012 | HY | Moody's upgrades Elan
|
12/14/2011 | SP | UBS changes Cusips for five upcoming offerings of airbag notes
|
12/12/2011 | SP | UBS to price 8.5%-11% airbag yield optimization notes linked to Elan
|
10/27/2011 | HYLM | Elan buys back $200 million of 83/4% senior notes due 2016 in October
|
10/17/2011 | HYLM | Elan asset sale and tender offer expires, all floaters redeemed
|
9/29/2011 | CV | S&P lifts Elan
|
9/29/2011 | HY | S&P upgrades Elan
|
9/16/2011 | HYLM | Elan subsidiaries offer to buy back four note series, call floaters
|
8/26/2011 | CVHY | S&P: Elan on positive watch
|
6/21/2011 | SP | New Issue: UBS prices $6.23 million 11.59% trigger yield optimization notes linked to Elan
|
6/14/2011 | SP | UBS plans 9.5%-12% trigger yield optimization notes linked to Elan
|
6/7/2011 | HYLM | Elan banking on big debt paydown using asset sale proceeds, sees $800 million debt target
|
5/9/2011 | HY | S&P: Elan on positive watch
|
5/9/2011 | HY | Moody's affirms Elan
|
11/29/2010 | SP | New Issue: Barclays prices $250,000 10% reverse convertibles linked to Elan
|
11/9/2010 | SP | Barclays to price 10% reverse convertibles linked to Elan
|
10/28/2010 | SP | New Issue: Barclays prices $500,000 14% reverse convertibles linked to Elan
|
10/27/2010 | HY | Elan continues to improve capital structure, focuses on reducing upcoming debt maturities
|
10/8/2010 | SP | Barclays to price 14% reverse convertibles linked to Elan
|
9/30/2010 | HYLM | Elan accepts all $156 million of tendered 8 7/8%, floating-rate notes
|
9/29/2010 | CVHY | S&P affirms Elan; outlook down to stable
|
8/30/2010 | HYLM | Elan tenders for up to $186 million 8 7/8% notes, floaters due 2013
|
8/17/2010 | HYLM | Elan to redeem remaining $300 million senior floating-rate notes
|
8/12/2010 | CVHY | S&P rates Elan notes B
|
8/12/2010 | CVHY | Moody's rates Elan notes B2
|
8/11/2010 | HYLM | Elan to use offering proceeds for redemption of floating-rate notes
|
8/11/2010 | HY | New Issue: Elan prices $200 million add-on to 83/4% notes due Oct. 15, 2016 at 96 to yield 9.62%
|
8/11/2010 | HY | S&P rates Elan notes B
|
8/11/2010 | HY | Market Commentary: First Data, OPTI, Peabody, Elan price; ILFC brings huge split-rated deal; new Tembecs tumble
|
8/9/2010 | BK | Elan to use proposed refinancing transaction to retire existing debt
|
5/17/2010 | SP | New Issue: RBC prices $0.1 million 20.5% reverse convertibles linked to Elan
|
5/13/2010 | SP | New Issue: RBC prices $0.9 million 25% reverse convertibles linked to Elan
|
5/12/2010 | SP | RBC increases coupon for RevCons linked to Elan Corp. stock to 20.5%
|
5/11/2010 | SP | Barclays to price 14.5% reverse convertibles linked to Elan
|
5/4/2010 | SP | RBC to price 14.25% reverse convertibles linked to Elan
|
4/29/2010 | SP | New Issue: Barclays prices $1 million 11% reverse convertibles linked to Elan
|
4/19/2010 | HY | Moody's: No change for Elan
|
4/12/2010 | SP | Barclays to price 11% reverse convertibles linked to Elan
|
3/30/2010 | SP | New Issue: RBC prices $50,000 13.5% reverse convertibles linked to Elan
|
3/30/2010 | SP | New Issue: Barclays prices $4 million 13.25% reverse convertibles linked to Elan
|
3/22/2010 | SP | RBC to price 13.5% reverse convertibles linked to Elan Corp. stock
|
3/17/2010 | SP | New Issue: RBC prices $496,000 13% reverse convertibles linked to Elan
|
3/8/2010 | SP | RBC to sell 13% three-month reverse convertibles linked to Elan stock
|
3/5/2010 | SP | Barclays to price 13.25% reverse convertibles linked to Elan
|
3/2/2010 | SP | New Issue: Barclays sells $10 million more 13% reverse convertibles linked to Elan
|
2/25/2010 | SP | New Issue: Barclays prices $2.5 million 13% reverse convertibles linked to Elan
|
2/25/2010 | SP | New Issue: RBC prices $0.16 million 13% reverse convertibles linked to Elan
|
2/10/2010 | BKBWHY | Elan reduces net debt to $650 million, enhances liquidity in 2009
|
2/8/2010 | SP | Barclays to price 13% reverse convertibles linked to Elan
|
2/8/2010 | SP | RBC to price 13% reverse convertibles linked to Elan
|
1/28/2010 | SP | New Issue: Barclays prices $1 million 13.75% reverse convertibles linked to Elan
|
1/28/2010 | SP | New Issue: RBC prices $0.52 million 17.5% reverse convertibles linked to Elan
|
1/28/2010 | SP | New Issue: RBC prices $0.25 million 7.2% reverse convertibles linked to Elan
|
1/14/2010 | SP | RBC plans to price 17.5% reverse convertibles linked to Elan stock
|
1/8/2010 | SP | Barclays to price 13.75% reverse convertibles linked to Elan
|
12/31/2009 | SP | New Issue: ABN Amro sells $35,000 14.35% reverse exchangeables linked to Elan
|
12/24/2009 | SP | New Issue: RBC prices $0.33 million 24% reverse convertibles linked to Elan
|
12/8/2009 | SP | RBC to price 24% reverse convertibles linked to Elan
|
12/7/2009 | SP | ABN Amro to price 14.35% reverse convertibles linked to Elan
|
10/30/2009 | SP | New Issue: RBC prices $0.69 million 35.5% reverse convertibles linked to Elan
|
10/29/2009 | HY | Elan subsidiaries accept tenders for $3.3 million more 73/4% notes
|
10/23/2009 | SP | RBC to price 20% reverse convertibles linked to Elan
|
10/19/2009 | SP | New Issue: RBC prices $0.27 million 18.75% reverse convertibles linked to Elan
|
10/14/2009 | HY | Elan subsidiaries get early tenders for $783.9 million of 73/4% notes
|
10/6/2009 | SP | RBC to price 18.75% reverse convertibles linked to Elan
|
9/30/2009 | HY | Market Commentary: Cincinnati Bell, TransDigm, CEVA price; Alon, Venoco hit the road; CIT down on bankruptcy buzz
|
9/29/2009 | HY | Elan subsidiaries start tender offer for $850 million 73/4% senior notes
|
9/29/2009 | SP | New Issue: RBC prices $0.19 million 22% reverse convertibles linked to Elan
|
9/29/2009 | CVHY | Moody's rates Elan notes B2
|
9/29/2009 | HY | New Issue: Elan Finance sells upsized $625 million 83/4% seven-year notes at 98.71 to yield 9%
|
9/29/2009 | HY | Market Commentary: Upsized Elan, Windstream, split-rated Gannett pace busy primary, new Windstream bonds move up
|
9/25/2009 | HY | Moody's upgrades Elan
|
9/21/2009 | SP | RBC to price 22% reverse convertibles linked to Elan
|
9/16/2009 | SP | New Issue: RBC prices $0.37 million 21.5% reverse convertibles linked to Elan
|
9/14/2009 | SS | Elan cures breach; Johnson & Johnson drops price for interest in company
|
9/4/2009 | HY | Market Commentary: Junk trading stalls ahead of holiday break; Blockbuster firmer; investors ponder Elan dilemma
|
9/4/2009 | HY | Market Commentary: Junk trading stalls ahead of holiday break; Blockbuster firmer; investors ponder Elan dilemma
|
9/4/2009 | SP | RBC to price 21.5% reverse convertibles linked to Elan
|
7/21/2009 | BKBWHYSS | Elan looking to be profitable, cash flow positive by year-end 2010
|
7/2/2009 | CVHY | Moody's reviews Elan
|
7/2/2009 | HY | Market Commentary: Elan jumps on J&J news; new Wind bonds a winner but Toys in trouble; funds add $385 million
|
7/2/2009 | SS | Johnson & Johnson to buy Elan's interest in Alzheimer's program
|
6/3/2009 | HY | Market Commentary: Upsized Domtar, Valeant price deals, Valeant moves up; junk surge slows; Ford keeps firming
|
6/1/2009 | HY | Market Commentary: Tenet, Interface price, others slate; GM bonds jump post Chapter 11; Elan up on buyout buzz
|
3/17/2009 | HY | Market Commentary: Wynn stock sale boosts bonds; Sprint gains continue; GM up further; MGM posts loss, gets waiver
|
2/10/2009 | BKBWHYSS | Elan hoping to sell minority equity position in company through strategic review
|
1/14/2009 | HY | Market Commentary: MetroPCS brings upsized deal, bonds trade up; Nortel gyrates on Chapter 11 filing; broad market lower
|
1/13/2009 | HY | Market Commentary: Isle of Capri jumps on partial tender offer; Neiman Marcus off on PIK interest decision; Nortel baffles investors
|
1/13/2009 | SS | Elan to consider strategic alternatives including possible sale
|
1/13/2009 | SS | Market Commentary: Elan moves closer to sale block; second bid for Genentech expected; Puget trades at discount to deal
|
1/12/2009 | HY | Market Commentary: Advanced Medical Optics flies on Abbott bid; Landry's off as CEO withdraw deal; Fresenius shops dollar/euro deal
|
1/9/2009 | HY | Market Commentary: Junk ends volatile week on up note; new Cablevisions add to gains; Elan, Lyondell up again
|
1/9/2009 | SS | Market Commentary: Analyst sees Elan, Pfizer combo unlikely; DOJ studies Centennial buyout; Crucell moves on deal talk
|
1/8/2009 | HY | Market Commentary: Cablevision brings upsized deal, bonds move up; junk mostly off; M&A buzz boosts Elan; funds soar $988 million
|
12/31/2008 | SP | New Issue: RBC prices $543,000 of 19% reverse convertibles linked to Elan
|
12/31/2008 | SP | New Issue: RBC prices $326,000 22% RevCons linked to Elan
|
12/12/2008 | SS | Elan shareholder asks for removal of CEO
|
10/30/2008 | HY | Market Commentary: MGM Mirage brings deal; GMAC gyrates on bank, debt plans, Rite Aid up on sales; funds lose $74 million
|
8/28/2008 | SP | New Issue: Lehman prices $0.173 million 25% reverse convertibles linked to Elan
|
8/15/2008 | HY | Market Commentary: MBIA moves up as S&P stands down; Abitibi bonds climb; debt pledge spurs Sprint interest
|
8/12/2008 | SP | Lehman to issue 25% reverse exchangeables linked to Elan
|
8/1/2008 | HY | Market Commentary: GM skids on big loss; Boyd booms on project delay; Elan, Idearc tumble anew; Clear Channel rolls bridge
|
8/1/2008 | SP | New Issue: Lehman prices $0.6 million 30% reverse convertibles linked to Elan
|
7/30/2008 | SP | New Issue: Barclays prices $2 million 14% reverse convertibles linked to Elan
|
7/30/2008 | SP | New Issue: RBC prices $0.36 million 20.75% reverse convertibles linked to Elan
|
7/30/2008 | HY | Market Commentary: Ferrellgas prices downsized deal; Elan down on disappointing drug data; Idearc bounces from lows
|
7/11/2008 | SP | Barclays to price 14% reverse convertibles linked to Elan
|
7/10/2008 | SP | Fortis to price 20.2% knock-in reverse convertibles linked to Elan
|
7/10/2008 | SP | RBC plans 20.75% reverse convertibles linked to Elan
|
6/27/2008 | SP | New Issue: Barclays prices $1.5 million 16.9% reverse convertibles linked to Elan
|
6/11/2008 | SP | New Issue: Barclays prices $4 million 16.4% reverse convertibles linked to Elan
|
6/10/2008 | SP | Barclays to price 16.9% reverse convertibles linked to Elan
|
5/29/2008 | SP | New Issue: RBC prices $300,000 19.5% RevCons linked to Elan
|
5/29/2008 | SP | New Issue: RBC prices $300,000 22.4% RevCons linked to Elan
|
3/27/2008 | SP | New Issue: Credit Suisse sells $1 million 13.5% reverse convertibles linked to Elan
|
3/10/2008 | SP | Lehman to issue 21% reverse exchangeables linked to Elan
|
3/5/2008 | SP | Barclays to price 19.5% reverse convertibles linked to Elan
|
3/3/2008 | SP | New Issue: ABN Amro prices $2 million 22.75% reverse convertibles linked to Elan
|
2/29/2008 | SP | New Issue: Bear Stearns sells $1 million 25% reverse convertibles linked to Elan
|
2/27/2008 | SP | Bear Stearns to price 25% reverse convertibles linked to Elan
|
2/26/2008 | CVHY | Moody's ups Elan outlook to positive
|
1/30/2008 | SP | New Issue: RBC prices $442,000 24.7% reverse convertibles linked to Elan
|
1/9/2008 | SP | RBC plans 24.7% reverse convertibles linked to Elan
|
1/8/2008 | SP | Fortis plans 25.5% reverse convertibles linked to Elan
|
12/10/2007 | SP | RBC plans 19% reverse convertibles linked to Elan
|
12/10/2007 | SP | RBC plans 22% reverse convertibles linked to Elan
|
11/28/2007 | SP | New Issue: RBC prices $230,000 18.05% reverse convertibles linked to Elan
|
11/19/2007 | SP | Fortis plans 19.2% reverse convertibles linked to Elan
|
11/15/2007 | SP | RBC pushes back maturity of planned 18.05% reverse convertibles linked to Elan
|
11/6/2007 | SP | RBC to price 18.05% reverse convertibles linked to Elan
|
11/5/2007 | SP | Barclays to price 20% reverse convertibles linked to Elan
|
10/31/2007 | SP | New Issue: ABN Amro sells $800,000 18.5% Knock-in Reverse Exchangeables linked to Elan
|
10/30/2007 | SP | New Issue: Barclays prices $1.25 million 19.5% reverse convertibles linked to Elan
|
10/30/2007 | SP | New Issue: RBC prices $185,000 19% reverse convertibles linked to Elan
|
10/16/2007 | SP | New Issue: Eksportfinans prices $158,000 17.75% reverse convertibles linked to Elan via Natixis
|
10/10/2007 | HY | S&P: Elan view positive
|
10/10/2007 | SP | Barclays to price 19.5% reverse convertibles linked to Elan
|
10/10/2007 | SP | New Issue: HSBC prices $150,000 25% reverse convertibles linked to Elan
|
10/2/2007 | SP | ABN Amro to price 18.5% reverse exchangeables linked to Elan
|
9/28/2007 | SP | Eksportfinans to price 17.75% reverse convertibles linked to Elan via Natixis
|
9/27/2007 | SP | New Issue: HSBC prices $525,000 of 25% reverse convertibles linked to Elan
|
9/27/2007 | SP | New Issue: RBC sells $1.18 million 21.3% reverse convertibles linked to Elan
|
9/26/2007 | SP | HSBC USA to price 25% reverse convertibles linked to Elan
|
9/10/2007 | SP | RBC to price 21.3% reverse convertibles linked to Elan
|
9/7/2007 | SP | New Issue: JPMorgan prices $600,000 20.018% reverse exchangeables linked to Elan
|
9/5/2007 | SP | New Issue: ABN Amro sells $4.5 million 36.75% Knock-in Reverse Exchangeables linked to Elan
|
9/5/2007 | SP | Fortis Bank plans 24% knock-in reverse convertibles linked to Elan
|
8/31/2007 | SP | New Issue: Barclays prices $1 million 15.75% reverse convertibles linked to Elan
|
8/30/2007 | SP | New Issue: RBC prices $1.11 million 19.15% reverse convertibles linked to Elan
|
8/30/2007 | SP | New Issue: RBC prices $272,000 27.95% reverse convertibles linked to Elan
|
8/28/2007 | SP | New Issue: Eksportfinans prices $784,000 20.05% reverse convertibles linked to Elan via Natixis
|
8/27/2007 | SP | New Issue: ABN Amro prices $2 million 24% reverse convertibles linked to Elan
|
8/27/2007 | SP | ABN Amro plans 36.75% reverse exchangeable securities linked to Elan
|
8/21/2007 | SP | ABN Amro to price 24% knock-in notes linked to Elan
|
8/8/2007 | SP | RBC to price 19.15% reverse convertibles linked to Elan
|
8/8/2007 | SP | RBC to price 27.95% reverse convertibles linked to Elan
|
8/6/2007 | SP | Eksportfinans to price 20.05% reverse convertibles linked to Elan via Natixis
|
7/26/2007 | HYSS | Elan planning to reduce cash costs by $40 million in response to generic competitors
|
7/25/2007 | SP | Barclays to price 15.75% reverse convertibles linked to Elan
|
7/23/2007 | SP | New Issue: Barclays prices $2 million 19% reverse convertibles linked to Elan
|
7/10/2007 | SP | Fortis Bank plans 20% knock-in reverse convertibles linked to Elan
|
7/6/2007 | SP | ABN Amro plans 14.9% knock-in notes linked to Elan
|
7/6/2007 | SP | New Issue: HSBC USA prices $1.524 million 14% reverse convertibles linked to four stocks
|
7/5/2007 | SP | Barclays to price 19% reverse convertibles linked to Elan
|
6/29/2007 | SP | New Issue: ABN Amro prices $2.1 million 22.25% knock-in notes linked to Elan
|
6/29/2007 | SP | New Issue: Barclays prices $1 million 19.5% reverse convertibles linked to Elan
|
6/28/2007 | SP | New Issue: JPMorgan prices $280,000 20% reverse exchangeables linked to Elan
|
6/27/2007 | SP | HSBC USA to price 14% reverse convertibles linked to four stocks
|
6/25/2007 | SP | Rabo to price 16.1% knock-in notes linked to Elan
|
6/11/2007 | SP | Barclays to price 19.5% reverse convertible notes linked to Elan
|
6/11/2007 | SS | Market Commentary: Medivation spikes; H&R Block props up Jackson Hewitt, Intuit; Ford up; Affiliated Computer up
|
6/5/2007 | SP | JPMorgan to price 20% six-month reverse exchangeables linked to Elan
|
6/5/2007 | SP | New Issue: Lehman prices $850,000 21.51% reverse exchangeables linked to Elan
|
6/5/2007 | SP | Market Commentary: HSBC, Rabobank plan certificates of deposit linked to index baskets
|
6/5/2007 | SP | ABN Amro plans 22.25% Knock-in Reverse Exchangeables linked to Elan
|
5/30/2007 | SP | New Issue: RBC sells $941,000 19.5% reverse convertibles linked to Elan
|
5/29/2007 | SP | New Issue: JPMorgan prices $2.721 million 25% reverse exchangeables linked to Elan
|
5/10/2007 | SP | RBC to price 19.5% reverse convertibles linked to Elan
|
5/8/2007 | SP | Rabo to price 19.4% knock-in reverse convertibles linked to Elan via LaSalle
|
5/8/2007 | SP | New Issue: Barclays prices $1.25 million 19.3% reverse convertibles linked to Elan
|
5/8/2007 | SP | JPMorgan to price 25% three-month reverse exchangeables linked to Elan
|
5/4/2007 | SP | ABN to sell 17.75% Knock-in Reverse Exchangeables linked to Elan
|
5/4/2007 | SP | New Issue: JPMorgan prices $0.7 million 28.5% reverse exchangeables linked to Elan
|
4/27/2007 | SP | New Issue: HSBC sells $1.381 million 25.25% reverse convertibles linked to Elan
|
4/27/2007 | SP | New Issue: RBC sells $904,000 18.25% reverse convertibles linked to Elan
|
4/27/2007 | SP | New Issue: ABN sells $1.775 million 16% knock-in notes linked to Elan
|
4/23/2007 | SP | Barclays to price 19.3% six-month reverse convertibles linked to Elan
|
4/16/2007 | SP | RBC to price 18.25% reverse convertibles linked to Elan
|
4/13/2007 | SP | Market Commentary: Lehman to price notes linked to Israeli shekel; Barclays plans S&P 500-linked notes
|
4/9/2007 | SP | Market Commentary: Exportfinans prices $27.561 million in notes linked to Topix index; Rabo plans 32.5% reverse convertibles
|
4/5/2007 | SP | HSBC to issue 25.25% reverse convertibles linked to Elan
|
4/4/2007 | SP | ABN Amro plans 16% reverse exchangeable securities linked to Elan
|
4/3/2007 | SP | Rabo to price 21% knock-in reverse convertibles linked to Elan via LaSalle
|
4/3/2007 | SP | Market Commentary: ABN Amro, Rabo to price slate of reverse convertibles with big coupons
|
3/27/2007 | SP | New Issue: ABN Amro sells $1 million 17.25% Knock-in Reverse Exchangeables linked to Elan
|
3/16/2007 | SP | ABN Amro revises terms, now 17.25% knock-in notes linked to Elan via LaSalle
|
3/6/2007 | SP | New Issue: HSBC issues $1.985 million 15% reverse convertibles linked to six stocks
|
3/5/2007 | SP | ABN Amro to price 21.5% knock-in notes linked to Elan via LaSalle
|
3/5/2007 | SP | HSBC to issue reverse convertibles linked to six stocks
|
2/27/2007 | SP | New Issue: ABN Amro prices $7.175 million 29.1% knock-in notes linked to Elan via LaSalle
|
2/27/2007 | SP | New Issue: JPMorgan prices $795,000 20% notes linked to Elan
|
2/26/2007 | SP | Market Commentary: ABN Amro prices 30% reverse exchangeables linked to Elan; Rabo plans notes linked to tech stocks
|
2/23/2007 | SP | New Issue: ABN Amro prices $2.75 million 30% knock-in notes linked to Elan
|
2/14/2007 | SP | Market Commentary: RBC to price 14.35% reverse convertibles linked to Marvell; higher coupons seen in reverse convertibles
|
2/13/2007 | SP | ABN Amro to issue 29.1% knock-in reverse notes linked to Elan
|
2/8/2007 | SP | JPMorgan to price 20% reverse exchangeables linked to Elan
|
12/14/2006 | CVHY | Elan holders convert $253.6 million 6.50% convertibles ahead of redemption; Athena calls 7.25% notes
|
12/6/2006 | HY | Market Commentary: Williams Partners prices $600 million deal; Movie Gallery bonds jump
|
12/6/2006 | SP | Rabo to price 15.25% reverse convertibles linked to Elan via LaSalle
|
11/21/2006 | SP | Market Commentary: Barclays prices reverse convertibles with high coupons; Svensk prices $32.97 million index-linked notes
|
11/21/2006 | SP | New Issue: Barclays sells $2 million 20% reverse convertibles linked to Elan
|
11/20/2006 | HY | Market Commentary: Upsized Lear deal prices, trades down; Freeport gyrates on Phelps Dodge deal
|
11/17/2006 | HY | New Issue: Elan Finance sells upsized $615 million two-part note offering
|
11/17/2006 | HY | Market Commentary: Rental Services, Elan, eircom deals price; airlines retreat, steel subdued despite M&A buzz
|
11/16/2006 | BT | Market Commentary: Elan bonds on tap; Acorda rises on acquisition buzz; Neurochem, CollaGenex, Dendreon sell PIPEs
|
11/15/2006 | HY | Market Commentary: Delta bonds soar on buyout bid, Northwest also; upsized GNC deal prices
|
11/15/2006 | BTHY | Elan sets price talk for $500 million two-part seven-year notes
|
11/13/2006 | HY | Market Commentary: Calpine continues gain on numbers; Tekni-Plex dips; KCS de Mexico prices
|
11/10/2006 | HY | Market Commentary: Bombardier, Sally, Griffin deals price; Remy bonds nosedive
|
11/9/2006 | BTCVHY | Elan plans redemption of $254 million 6.5% convertibles, some 71/4% notes
|
11/9/2006 | BT | Market Commentary: Thermage, ActivBiotics IPOs on tap at lower ranges; Millennium, Elan market bonds; Vasogen off
|
11/9/2006 | BTCVHY | S&P gives Elan Finance notes B
|
11/9/2006 | BTCVHY | Moody's rates Elan notes B3
|
11/9/2006 | HY | Market Commentary: HCA prices $5.7 billion deal; Dana jumps on plant-closing plans; funds see $39 million inflow
|
11/9/2006 | BTHY | Elan Finance to start roadshow Monday for $500 million seven-year notes
|
11/7/2006 | BT | Elan increasing operating leverage to allow for eventual benefit from Tysabri
|
11/3/2006 | SP | Barclays to price 20% reverse convertibles linked to Elan
|
10/27/2006 | BT | Elan still at sell for Merrill
|
10/25/2006 | BT | Elan kept at sell by Merrill
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
10/2/2006 | SP | LaSalle to price 20% reverse convertibles linked to Elan for Rabo
|
10/2/2006 | BT | Merrill: 60% of those surveyed have prescribed Tysabri for MS
|
9/29/2006 | BT | Biogen announces three Tysabri trial results at European MS conference
|
9/27/2006 | BT | Merrill retains Elan at sell
|
9/27/2006 | BT | Elan, Transition Therapeutics to develop Alzheimer's disease drug
|
9/15/2006 | SP | Rabo plans issue of 20% knock-in reverse convertibles linked to Elan
|
9/15/2006 | SP | Market Commentary: Rabo plans 20% knock-in reverse convertibles tied to Elan; RBC selling notes linked to global index basket
|
9/14/2006 | BT | Elan kept at sell by Merrill
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
8/4/2006 | BT | Merrill retains Elan at sell
|
8/4/2006 | BT | Merrill retains Elan at sell
|
8/3/2006 | BT | Merrill puts Elan at sell
|
8/1/2006 | BT | Merrill keeps Elan at sell
|
8/1/2006 | BTCVHY | Elan posts improved net loss of $90.5 million for second quarter
|
7/24/2006 | BT | Biogen Idec, Elan say Tysabri available to treat relapsing forms of multiple sclerosis
|
7/13/2006 | BT | Elan to work with Archemix to develop aptamer therapeutics for autoimmune disease
|
7/6/2006 | BT | Elan, Abbott sign licensing deal to use NanoCrystal technology to combine cholesterol drugs
|
6/29/2006 | BT | Biogen, Elan receive EU approval for Tysabri in treatment of multiple sclerosis
|
6/15/2006 | BTCVHY | Moody's lifts Elan view to stable
|
6/7/2006 | BT | Elan keeps sell rating from Merrill
|
6/6/2006 | BT | Biogen, Elan expect data, prescription program to advance Tysabri reintroduction
|
6/6/2006 | HY | Market Commentary: UGS PIK floater prices; builders struggle; Avondale jumps in otherwise dull market
|
6/5/2006 | BT | Biogen, Elan receive FDA approval to reintroduce Tysabri for MS
|
6/5/2006 | BT | Market Commentary: Genelabs stock skyrockets on Novartis collaboration; Antigenics stock falls on phase 3 Oncophage data
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
5/12/2006 | HY | Market Commentary: GM gyrates on Delphi concerns; Movie Gallery climb continues; American Greetings plans deal
|
5/5/2006 | BT | Elan kept at sell by Merrill
|
5/4/2006 | BT | Elan's first-quarter revenues up 31%, net loss decreases 71%
|
5/4/2006 | BT | Elan keeps sell rating from Merrill
|
4/28/2006 | HY | Market Commentary: ISS prices upsized two-parter; Canadian forest bonds up on trade agreement; Elan better on Tysabri news
|
4/28/2006 | BT | Biogen Idec, Elan: European committee issues positive opinion for Tysabri to treat multiple sclerosis
|
4/28/2006 | BT | Elan retained at sell by Merrill
|
4/6/2006 | BT | Biogen Idec, Elan find quality of life benefits in phase 3 trial of Tysabri for MS
|
3/29/2006 | BT | Biogen, Elan resume Tysabri clinical trial
|
3/22/2006 | BT | Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
|
3/22/2006 | HY | Market Commentary: MGM sells upsized two-parter; GM steady, Delphi up on employee buyout plan
|
3/22/2006 | BT | Biogen Idec, Elan say FDA needs more time to review Tysabri risk plan for multiple sclerosis
|
3/22/2006 | BT | Elan at sell by Merrill
|
3/15/2006 | BT | Market Commentary: Cell Genesys rises then ends off; Critical Therapeutics loses 2%; Siga up 10%; Corautus rebounds
|
3/9/2006 | BT | Market Commentary: NPS Pharma weak ahead of FDA; Dyax plunges; Insmed up slightly; Vertex dives; Elan off, Biogen up
|
3/9/2006 | HY | Market Commentary: Level 3 prices two-part deal; GM jumps on Delphi deal report; funds see $185 million outflow
|
3/9/2006 | BT | Citigroup reiterates Elan at sell
|
3/9/2006 | BT | Elan sell rating unchanged by Merrill
|
3/8/2006 | BT | Merrill keeps Elan at sell
|
3/8/2006 | BT | Market Commentary: Alexza IPO gets off; Cepheid off; Dyax deal seen; Elan, Biogen up; Neurocrine shakes off trial miss
|
3/8/2006 | HY | Market Commentary: Levi plans deal, Longview offering spiked; Elan up on Tysabri news
|
3/8/2006 | BT | Biogen, Elan say FDA committee votes to reintroduce Tysabri for multiple sclerosis
|
3/6/2006 | BT | Merrill keeps Elan at sell
|
3/6/2006 | BT | Market Commentary: Cubist players hedging bets with puts; Insmed follow-on emerges; Elan up; Titan zooms; LifeCell up
|
3/1/2006 | BT | Biogen, Elan give update on trials, safety study for multiple sclerosis drug Tysabri
|
3/1/2006 | BT | Elan at sell by Merrill
|
3/1/2006 | BT | Citigroup keeps Elan at sell
|
2/28/2006 | BT | Elan to suspend trading during FDA product review for Tysabri
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/28/2006 | HY | Market Commentary: ArvinMeritor climbs on tender news; Longview deal hits the road
|
2/16/2006 | BT | Market Commentary: Adolor up on heavy volume after deal; Avigen sinks; Biogen, Elan react to Tysabri news; Onyx slips
|
2/16/2006 | HY | Market Commentary: Penney gains on credit upgrade; Steinway prices eight-year deal; funds see $116 million outflow
|
2/16/2006 | BT | Citigroup reiterates Elan at sell
|
2/15/2006 | BT | Biogen, Elan announce FDA lifts hold on Tysabri trial for MS
|
2/9/2006 | BT | Elan sells Prialt's European rights to Eisai
|
2/1/2006 | BT | Merrill retains Elan at sell
|
1/31/2006 | HY | Market Commentary: Ineos prices downsized two-parter, Chesapeake prices also; Adelphia moves up
|
1/31/2006 | BT | Elan rated at sell by Citigroup
|
1/31/2006 | BT | Merrill retains Elan at sell
|
1/27/2006 | BT | Elan reiterated at sell by Citigroup
|
1/23/2006 | BT | Biogen, Elan say FDA to review Tysabri for multiple sclerosis in March
|
1/23/2006 | HY | Market Commentary: Ford jump-starts auto sector; Albertson's dives on sale news; NRG deal talk out
|
1/10/2006 | BT | Elan, EntreMed sign agreement for Panzem NCD oncology product
|
11/18/2005 | BT | Citigroup maintains Elan at sell
|
11/18/2005 | BT | Merrill maintains Elan at sell
|
11/18/2005 | CV | Market Commentary: Sonic, CompuCredit edge higher; Doral Financial surges amid rumors; Protein Design gains
|
11/18/2005 | HY | Market Commentary: General Motors, Elan bonds up; downsized Team Health deal prices
|
11/17/2005 | BT | Biogen Idec, Elan say FDA accepts Tysabri application for priority review to treat multiple sclerosis
|
10/28/2005 | BT | Citigroup reiterates sell rating for Elan
|
10/28/2005 | BT | Merrill Lynch maintains Elan at sell
|
10/27/2005 | BT | Merrill reiterates Elan sell rating
|
10/27/2005 | CV | Market Commentary: GM bonds lower, credit widens on bankruptcy scare; Digital River plunges; Par Pharma in
|
10/27/2005 | BTCVHY | Elan narrows Q3 loss; eyes '06 relaunch of Tysabri; watching costs, capital structure closely
|
10/17/2005 | BT | No new PML cases in patients taking Tysabri, Elan, Biogen say
|
10/17/2005 | BT | Market Commentary: Chiron falls big after closing bell; Biogen, Elan gain; Cephalon up
|
9/27/2005 | BT | Market Commentary: Sunesis sinks after below-range IPO; Biogen, Elan bounce then retreat; Genentech sharply lower
|
9/13/2005 | BT | Elan maintained by Merrill Lynch at sell
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
8/11/2005 | BT | Market Commentary: Coley, China Medical ease back; Mpex announces venture capital; Kosan slips; Elan issues retreat
|
8/9/2005 | BT | Market Commentary: Elan, Biogen Idec up on Tysabri update; Human Genome convertible rises; Celgene, King Pharma gain
|
8/9/2005 | HY | Market Commentary: Elan gains on Tysabri news; United Rentals on earnings; Dollarama, Lamar deals price
|
7/28/2005 | BT | Elan reiterated by Merrill Lynch at sell
|
7/28/2005 | BT | Market Commentary: Advanced Life Sciences IPO cut; ZymoGenetics plans follow-on; Elan plunges on credit worries
|
7/28/2005 | HY | Market Commentary: FTI prices upsized 8-year deal; Northwest bonds up, Dura down; funds see $105 million outflow
|
7/28/2005 | BTCVHY | Elan reports wider Q2 loss, but touts debt reduction; says Tysabri safety review moving along
|
7/27/2005 | BT | Elan reiterated by Smith Barney at sell
|
7/27/2005 | BT | Market Commentary: Theravance rises; NPS Pharma off; Advanced Life Sciences IPO on for Thursday; Elan, Biogen slightly higher
|
7/27/2005 | CV | Market Commentary: L-3 Communications deal on tap; Manor Care issue trades to 102.5 bid; Delta Air dives to mid-20s
|
7/27/2005 | HY | Market Commentary: SunGard prices two separate mega-deals, L-3 comes as well; Delta dives on more bankruptcy talk
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|
7/13/2005 | BT | Serono may progress while Tysabri slows, Merrill bio/pharma earnings preview says
|
6/30/2005 | BT | Elan reiterated by Merrill Lynch at sell
|
6/30/2005 | BT | Market Commentary: Elan shares move up, credit lags, Connetics rises against the tide; Medicis, Inamed up; Millipore off
|
6/21/2005 | BT | Market Commentary: Critical Therapeutics zooms after financing round; Mylan launches bank facility; Eyetech seen higher
|
6/16/2005 | BT | Market Commentary: Pfizer purchase spurs speculative buying; Cubist advances; ev3, Micrus, Gentium IPOs discounted
|
6/13/2005 | DD | Market Commentary: Airlines bonds tumble but traffic light; UAL paper drifts lower; Calpine bonds creep higher
|
6/13/2005 | HY | Market Commentary: Tenaska, Rafaella price deals; Calpine continues climb; Northwest Airlines hits downdraft
|
6/9/2005 | DD | Market Commentary: Elan bonds rise on Tysabri return hopes; Federal-Mogul loan trades around
|
6/9/2005 | HY | Market Commentary: MGM Mirage sells $500 million drive-by; Calpine up on tender; funds see 2nd straight inflow, $109 million
|
6/6/2005 | DD | Market Commentary: Delta bonds lower as oil stays near $55; DS Waters bank debt up on sale rumors
|
6/3/2005 | DD | Market Commentary: Airline bonds better on UAL profit prediction; Adelphia bank debt trades around
|
6/2/2005 | CV | Market Commentary: Cephalon suffers in aftermarket; Joy Global pulled; Symmetricom at bat; Elan retreats on drug news
|
6/2/2005 | DD | Market Commentary: Electricity names continue to empower distressed market; Elan down on new problem with drug
|
6/2/2005 | HY | Market Commentary: Autos continue upward, Elan plunges; TECO sells drive-by; funds end losing run with $976 million inflow
|
6/1/2005 | DD | Market Commentary: Distressed auto loans, bonds up despite GM, Ford woes; Elan up on debt paydown news
|
6/1/2005 | CVHY | Elan buys back $206 million convertibles, $36.8 million Athena notes
|
6/1/2005 | CV | Market Commentary: Cephalon in overnight market; Elan bounces; Beazer better; airline paper dips
|
5/23/2005 | DD | Market Commentary: Airline bonds remain aloft; Exide falls with stock slide; filibuster compromise may save asbestos bill
|
4/12/2005 | DD | Market Commentary: Asbestos names jump as claims bill deal seems near; Elan up on positive report about drug
|
4/1/2005 | DD | Market Commentary: Owens Corning bonds falter but bank debt holds; airlines fall on oil price rise
|
3/31/2005 | DD | Market Commentary: Elan bonds thrash around on new MS drug problem; Muzak off on delayed 10-K; Mirant loans rally
|
3/31/2005 | CV | Market Commentary: Saks gains on asset sale buzz; UTStarcom hit by restatement; Elan dives on drug death; ACE starts trading
|
3/31/2005 | CVDDHY | S&P: Elan unaffected
|
3/31/2005 | CVDDHY | S&P: Elan unit converts unchanged
|
3/9/2005 | HY | Market Commentary: Delta Petroleum deal prices, Telcordia cancelled; Crompton up on merger, Radnor dives
|
3/8/2005 | DD | Market Commentary: aaiPharma bonds swoon, although no news seen; Elan, Collins & Aikman continue rebound
|
3/7/2005 | HY | Market Commentary: Levi prices two-part deal; Collins & Aikman bounces, Elan also
|
3/7/2005 | CV | Market Commentary: Genworth synthetic coming; Cell Therapeutics dives; Celgene rises; Saks bagged up; Lions Gate higher
|
3/7/2005 | DD | Market Commentary: Elan bonds bounce after last week's fall; Mirant loans weaker
|
3/4/2005 | CV | Market Commentary: Allied Waste trades up from par; Nash Finch launches deal; Elan slides, Biogen steadier on news
|
3/4/2005 | HY | Market Commentary: Levi tinkers with offering; Elan falls on new drug woes; Delphi threatened with junk status
|
3/1/2005 | HY | Market Commentary: Elan bonds continue retreat; Cablevision bonds off on VOOM confusion
|
3/1/2005 | CV | Market Commentary: Charter falters on earnings; XM Satellite up as volatility play; Ford, GM lower but Chrysler up
|
3/1/2005 | CVDDHY | Moody's affirms Elan
|
2/28/2005 | CVDDHY | S&P: Elan view now stable
|
2/28/2005 | DD | Market Commentary: Collins & Aikman bonds continue retreat; Elan bonds nosedive on drug news
|
2/28/2005 | HY | Market Commentary: Elan bonds swoon on problems with MS drug; restructured Rural/Metro deal prices
|
2/28/2005 | CV | Market Commentary: Elan hurt, Biogen stable; Teva up, Schering slips; King trips; Yellow skids; Manpower lower; Saks off
|
12/7/2004 | CV | Market Commentary: CMS new deal bid at issue; Dress Barn bid up 3.5 points; Seacor launches overnighter
|
11/30/2004 | HY | Elan completes tenders for series B, series C guaranteed notes
|
11/23/2004 | CVDDHY | S&P ups Elan notes to B, converts to CCC+
|
11/22/2004 | CVDDHY | Moody's ups Elan, units
|
11/17/2004 | HY | Elan gets tenders, consents from 90% of series B, series C notes
|
11/11/2004 | HY | Elan receives consents to amend Elan Pharmaceutical III notes
|
11/10/2004 | HY | New Issue: Elan upsizes to $1.15 billion: $850 million fixed yields 73/4%, $300 million floater at Libor plus 400 bps
|
11/10/2004 | HY | Market Commentary: Elan prices upsized two-part offering; Collins & Aikman falls
|
11/8/2004 | HY | Market Commentary: Citizens Communications prices greatly upsized deal; Portola bounces around at lower levels
|
11/8/2004 | HY | Elan $850 million seven-year fixed-rate notes talked 73/4%-8%, floater talked Libor plus 400-425 bps
|
11/2/2004 | CV | Moody's rates Elan notes B3
|
11/1/2004 | CVDDHY | S&P rates Elan notes B-
|
11/1/2004 | HY | Elan to begin roadshow for new $850 million two-part deal via Morgan Stanley-led syndicate
|
11/1/2004 | HY | Market Commentary: Level 3 bonds rise on buyback scheme; L-3 sells upsized quickie deal
|
10/29/2004 | CVDDHY | Moody's may upgrade Elan
|
10/28/2004 | HY | Elan announces $850 million offering of seven-year notes
|
10/28/2004 | HY | Market Commentary: Delta flies on pilot deal; Ready Mixed, downsized Ad Directories price; funds see $56.5 million inflow
|
10/28/2004 | HY | Elan tenders for $351 million Elan Pharmaceutical III notes
|
10/18/2004 | CV | Market Commentary: Sirius convertibles up on Ford news; Elan active, edges up on Biogen buzz; CNet gains
|
10/11/2004 | CV | Market Commentary: Northwest, Delta lead lower on fuel prices, pilot contract concerns; drug paper higher
|
7/26/2004 | CV | Market Commentary: King Pharma soars on merger; Boise Cascade higher on split; Marshall & Ilsley deal emerges
|
4/16/2004 | CVDDHY | Moody's: Elan outlook positive
|
3/17/2004 | CV | Market Commentary: Cytyc goes to 104.375; XL prices at tight end of revised talk; Saks, Greater Bay, CommScope appear
|
2/18/2004 | CV | Market Commentary: CP Ships, Sovereign on tap early Thursday; El Paso, Primus beaten down; Corixa eyed in biotech rally
|
2/13/2004 | CVHY | S&P: Elan unaffected by divestiture
|
2/3/2004 | CVDDHY | S&P revises Elan to positive
|
12/16/2003 | CV | Elan says $799.7 million LYONs put back to company
|
11/24/2003 | CV | Market Commentary: Market hunts for Thanksgiving deal, Ciber answers the call with small issue; trading flow low
|
11/14/2003 | CV | Elan to pay LYONs put in cash
|
11/13/2003 | CVDDHY | Moody's revises Elan outlook to stable
|
11/12/2003 | CV | Market Commentary: AmeriCredit prices at wide end, Chesapeake at aggressive end; Casual Male bid up in gray
|
11/4/2003 | CV | Market Commentary: Navigant trades north of 107 on lack of supply; Actuant up 2 points in gray market action
|
11/3/2003 | CV | Market Commentary: American Tower gains 2.25 points on junk bond deal; three small new deals emerge
|
10/31/2003 | CV | Market Commentary: New Elan issue is a treat, zooming past 110 in heavy U.S. trading activity
|
10/31/2003 | CVDDHY | S&P ups Elan senior debt to B-
|
10/31/2003 | CV | New Issue: Elan upsized $400 million convertible yields 6.5%, up 49.9%, greenshoe exercised
|
10/30/2003 | CV | Elan sells upsized $400 million convertible to yield 6.5%, up 49.9%
|
10/30/2003 | CV | Market Commentary: Northwest reoffered at 98, edges up slightly; Elan is a blowout at 6.5%, up 49.9%
|
10/30/2003 | CVDDHY | S&P puts Elan on positive watch, rates convertible CCC
|
10/30/2003 | HY | Market Commentary: Silgan, O'Charley's price deals; Elan, Levi firmer, Biovail off on earnings; funds essentially flat
|
10/29/2003 | CV | Elan plans $250 million convertible to fund LYONs put
|
10/29/2003 | CV | Market Commentary: Gilead plunges 11-30 points on earnings disappointment; Northwest, Elan deals pops up;
|
10/29/2003 | DD | Elan to pay noteholders $16.8 million for allowing convertibles sale
|
9/8/2003 | CV | Market Commentary: Convertible players watch issues gain with stocks; selling subsides; RF Micro gains on better guidance
|
9/5/2003 | CVDDHY | S&P upgrades Elan
|
9/4/2003 | DDHY | Elan to file annual report, curing default
|
8/29/2003 | DDHY | Elan noteholders further extend waiver
|
8/22/2003 | DDHY | Elan noteholders further extend waiver
|
8/15/2003 | DDHY | Elan noteholders further extend waiver
|
8/8/2003 | DDHY | Elan noteholders extend waiver
|
7/30/2003 | DDHY | Elan obtains waiver from noteholders through Aug. 8
|
7/30/2003 | CVDDHY | S&P says Elan unchanged
|
7/18/2003 | CVDDHY | Fitch raises AES Gener outlook
|
6/26/2003 | CV | S&P rates new Sealed Air convert BBB
|
6/12/2003 | CV | Avon calls 0% convertibles
|
6/12/2003 | HY | Market Commentary: NVR sets new yield record; Calpine up on financing; $1.329 billion inflow is 2nd straight 10-digit gain
|
6/9/2003 | CV | Market Commentary: Week begins slowly with a thin market; Omnicare prices, three more small deals emerge
|
5/21/2003 | CV | Market Commentary: Providian's new paper soars to 104.5; Elan gains on deal for King sale; new deals continue to flow
|
4/2/2003 | BKCVHY | Moody's puts Corrections Corp. on upgrade review
|
4/2/2003 | CV | Market Commentary: Allied Waste deal stands pat; energy names firm on hope from Reliant's bank victory
|
3/21/2003 | CV | Market Commentary: HealthSouth converts trade in the 20s but more downside expected; Liberty/AOL prices at discount
|
3/18/2003 | CV | Market Commentary: Mandalay prices at record premium among flurry of new deals; secondary players in hiding
|
1/30/2003 | CV | S&P raises Lennar to investment grade
|
1/30/2003 | CV | Market Commentary: Micron trading lighter as outright buyers hold on; several drug issues gain
|
1/30/2003 | CV | Elan buys back LYONs for $150 million
|
1/30/2003 | HY | S&P raises Lennar to investment grade
|
1/13/2003 | HY | Market Commentary: Georgia-Pacific eases on guidance, asbestos concerns; Houghton Mifflin, Premcor ready deals
|
1/2/2003 | CV | Market Commentary: Market unexpectedly lively as new year opens strongly
|
11/14/2002 | CV | Fitch ups Nextel outlook
|
11/14/2002 | HY | S&P cuts Corus to junk
|
10/2/2002 | CV | Elan, Terayon, CNET in S&P list of B- credits near high default risk
|
7/31/2002 | HY | Moody's cuts Reliant Resources to junk
|
7/31/2002 | CV | S&P puts Avaya on negative watch
|
7/31/2002 | CV | Market Commentary: Market mixed, watching telecoms as Corning deal approaches
|
7/10/2002 | CV | Moody's cuts Elan to B2
|
7/10/2002 | HY | Moody's cuts Qwest
|
7/2/2002 | CV | S&P cuts WorldCom ratings
|
7/2/2002 | HY | Moody's puts Levi Strauss on review
|
7/2/2002 | BK | Moody's puts Levi Strauss on review
|
7/1/2002 | CV | S&P rates Mirant convertible at BBB-
|
6/10/2002 | CV | Fitch cuts Tyco ratings to junk
|
4/12/2002 | CV | Market Commentary: Quiet session ends quiet week on higher note; Cendant lower on accounting questions
|
3/26/2002 | CV | Moody's cuts DDi, rates new convertible at Caa1
|
3/19/2002 | CV | Moody's cuts Elan senior debt to Ba2
|
2/20/2002 | CV | Market Commentary: Convertibles bounce sparks new deal buzz, AmerUs emerges
|
2/13/2002 | CV | Moody's puts Cox on downgrade review
|
2/8/2002 | CV | Market Commentary: Convertibles still thin, but get lift from late stock rally
|
2/7/2002 | CV | Market Commentary: Convertibles flat, gridlocked on unsettling events
|
2/6/2002 | CV | Fitch cuts Markel convertibles to BBB-
|
2/6/2002 | CV | Market Commentary: Convertibles slide as credit concerns continue to weigh
|
2/5/2002 | CV | Fitch cuts Sprint senior unsecured to BBB from BBB+
|
2/5/2002 | CV | Market Commentary: Convertibles fall on credit concerns, Tyco battered again
|
2/4/2002 | CV | Market Commentary: Convertibles plunge as stocks dive, Solutia nixes new deal
|
1/30/2002 | CV | Market Commentary: Convertibles snap back somewhat but witch-hunt continues
|
1/18/2002 | CV | Market Commentary: Convertibles retreat, healthcare issues hit hard, Tyco takes wild ride
|
11/6/2001 | CV | Market Commentary: Convertible market gains with stocks on rate cut, new deals
|